| Dokumentenart: | Artikel | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Journal of Cancer Research and Clinical Oncology | ||||||||||||||||||||||||||||||||||||||||||||||
| Verlag: | SPRINGER | ||||||||||||||||||||||||||||||||||||||||||||||
| Ort der Veröffentlichung: | NEW YORK | ||||||||||||||||||||||||||||||||||||||||||||||
| Band: | 133 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 3 | ||||||||||||||||||||||||||||||||||||||||||||||
| Seitenbereich: | S. 153-167 | ||||||||||||||||||||||||||||||||||||||||||||||
| Datum: | 2007 | ||||||||||||||||||||||||||||||||||||||||||||||
| Institutionen: | Chemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmazeutische / Medizinische Chemie II (Prof. Buschauer) Chemie und Pharmazie > Institut für Pharmazie > Lehrstuhl Pharmazeutische / Medizinische Chemie II (Prof. Buschauer) | ||||||||||||||||||||||||||||||||||||||||||||||
| Sonstige Projekte: | SFB 234 | ||||||||||||||||||||||||||||||||||||||||||||||
| Identifikationsnummer: |
| ||||||||||||||||||||||||||||||||||||||||||||||
| Klassifikation: |
| ||||||||||||||||||||||||||||||||||||||||||||||
| Stichwörter / Keywords: | TUMOR-INHIBITING ACTIVITY; ANTITUMOR-ACTIVITY; BREAST-CANCER; <1,2-BIS(2,6-DIHALO-3-HYDROXYPHENYL)ETHYLENEDIAMINE>PLATINUM(II) COMPLEXES; PARENTERAL ESTROGEN; ANDROGEN ABLATION; ENDOCRINE THERAPY; CELL-LINES; CARCINOMA; MODEL; [1,2-diphenylethylenediamine] platinum(II) complexes; cisplatin; diethylstilbestrol; anti-prostate cancer activity; mode of action | ||||||||||||||||||||||||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie 500 Naturwissenschaften und Mathematik > 540 Chemie | ||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Veröffentlicht | ||||||||||||||||||||||||||||||||||||||||||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||||||||||||||||||||||||
| An der Universität Regensburg entstanden: | Ja | ||||||||||||||||||||||||||||||||||||||||||||||
| Dokumenten-ID: | 4785 |
Web of ScienceZusammenfassung
[Meso-1,2-bis(2,6-dihalo-3/4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-1-PtLL': 2,6-F-2,3-OH; meso-2-PtLL': 2,6-F-2,4-OH; meso-3-PtLL': 2,6-Cl-2,3-OH; meso-4-PtLL': 2,6-Cl-2,4-OH; L = OH2, L' = OSO3 or L,L' = Cl-2) were designed with the aim to get drugs comprising both cytotoxic and testosterone level lowering potencies. It is assumed that such compounds are more efficient than ...
Zusammenfassung
[Meso-1,2-bis(2,6-dihalo-3/4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-1-PtLL': 2,6-F-2,3-OH; meso-2-PtLL': 2,6-F-2,4-OH; meso-3-PtLL': 2,6-Cl-2,3-OH; meso-4-PtLL': 2,6-Cl-2,4-OH; L = OH2, L' = OSO3 or L,L' = Cl-2) were designed with the aim to get drugs comprising both cytotoxic and testosterone level lowering potencies. It is assumed that such compounds are more efficient than the established endocrine therapeutic measures and can affect the development of hormone refractory prostate cancer (PC). With exception of meso-3-PtLL' all Pt-complexes and the comparison compound cisplatin significantly reduced the testosterone level in experiments on male rats. However, in the test on the Dunning R3327 PC of the rat only cisplatin and meso-4-PtLL' showed a significant anti-tumor activity at well-tolerated dose ranges. Meso-4-PtLL' also significantly extended the time to disease progression in comparison with orchiectomy in this tumor model. Interestingly, the relapsed tumor, too, responded to meso-4-PtLL' as demonstrated in a long-term study on orchiectomized rats bearing Dunning R3327 PC grafts. This effect cannot be ascribed to cytotoxic effects of meso-4-PtLL' because of its inactivity on the human LNCaP/FGC PC cell line. Therefore, the contribution of an additional mechanism to the anti-prostate cancer activity of meso-4-PtLL', presumably owing to its estrogenic potency, must be considered. This assumption was supported by test results with diethylstilbestrol (DES) (non-steroidal estrogen) on the Dunning R3327 PC of the rat relapsed after orchiectomy. This tumor model was strongly inhibited by DES. The possible mode of action of meso-4-PtLL' is thoroughly discussed.
Metadaten zuletzt geändert: 29 Sep 2021 07:28
Altmetric